Can Fite Biofarma (Can Fite Biofarma) EBIT per Share

: $-1.96 (TTM As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

Can Fite Biofarma's EBIT per Share for the three months ended in Dec. 2023 was $-0.37. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.96.

During the past 3 years, the average EBIT per Share Growth Rate was 45.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was 48.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was 36.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Can Fite Biofarma's EBIT per Share or its related term are showing as below:

CANF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -14.8 Med: 22.4 Max: 55.3
Current: 45.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Can Fite Biofarma was 55.30% per year. The lowest was -14.80% per year. And the median was 22.40% per year.

CANF's 3-Year EBIT Growth Rate is ranked better than
91.03% of 1304 companies
in the Biotechnology industry
Industry Median: 3.35 vs CANF: 45.50

Can Fite Biofarma's EBIT for the three months ended in Dec. 2023 was $-1.83 Mil.

Can Fite Biofarma EBIT per Share Historical Data

The historical data trend for Can Fite Biofarma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-41.98

-11.83

-6.96

-3.71

-1.92

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share																-1.13	-0.69	-0.44	-0.46	-0.37

Can Fite Biofarma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Can Fite Biofarma's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.195	/	4.261
=	-1.92

Can Fite Biofarma's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.834	/	4.946
=	-0.37

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.96

Can Fite Biofarma (AMEX:CANF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Can Fite Biofarma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).